CN1520286B - Gastric retention controlled drug delivery system - Google Patents

Gastric retention controlled drug delivery system Download PDF

Info

Publication number
CN1520286B
CN1520286B CN028128575A CN02812857A CN1520286B CN 1520286 B CN1520286 B CN 1520286B CN 028128575 A CN028128575 A CN 028128575A CN 02812857 A CN02812857 A CN 02812857A CN 1520286 B CN1520286 B CN 1520286B
Authority
CN
China
Prior art keywords
drug delivery
delivery system
gastric retention
controlled drug
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN028128575A
Other languages
Chinese (zh)
Other versions
CN1520286A (en
Inventor
卡姆莱森·莫哈拉·德戴拉
尼汀·柏拉查丹·戴蒙迪卡尔
维沙里·维滋·戴维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharma Advanced Research Co Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of CN1520286A publication Critical patent/CN1520286A/en
Application granted granted Critical
Publication of CN1520286B publication Critical patent/CN1520286B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a gastric retention controlled drug delivery system comprising: (a) a controlled release core comprising a drug, a highly swellable polymer and a gas generating agent, said core being capable of swelling and achieving floatation rapidly while maintaining its physical integrity in gastrointestinal fluids for prolonged periods, and (b) a rapidly releasing coat composition comprising the same drug as in the core and pharmaceutically acceptable excipients, wherein the coating composition surrounds the core such that the system provides a biphasic release of the drug in gastrointestinal fluids.

Description

Gastric retention controlled drug delivery system
The present invention relates to a kind of gastric retention controlled drug delivery system that two stages disengaged mode that has.
Background of invention
The controlled drug delivery system carries medicine to form medicable effective ingredient haemoconcentration to health, in case after reaching such haemoconcentration, the controlled drug delivery system is carried medicine with the speed identical with the speed of health consumption medicine to health, thereby continues to keep for a long time constant haemoconcentration.By avoiding the fluctuating of the haemoconcentration that traditional application method follows, the controlled drug delivery system has reduced the generation of retroaction or side effect.The more important thing is that the controlled drug delivery system can reduce the medication frequency, for patient provides convenience according to the medication dose and the medication of following the doctor's advice.
As everyone knows, oral controlled drug delivery system is different to speed and its speed to the drug delivery of test water liquid of blood drug delivery, because the acid-base value of body fluid in the intestines and stomach, composition and agitation strength are with the ad-hoc location of drug release system in gastrointestinal tract, i.e. ad-hoc location from the stomach to the colon, with on an empty stomach or the quantity of the kind of the feed state and the thing of taking food and absorption change, the while also varies with each individual.In addition, medicine is not absorbed with speed in the same way in the process from the stomach to the colon.Some medicine has " absorption window ", and promptly they can only be absorbed on gastrointestinal top, and the absorption in colon that also has is unequal incomplete.Therefore, the position of controlled drug delivery system in gastrointestinal tract, and the key factor that need consider when all being the oral controlled drug delivery system of exploitation of the translational speed of controlled drug delivery system from the stomach to the colon.Therefore, the professional knows that the oral controlled medicine that disengages of exploitation not only will control medicine and disengage release rate (time control) in the time, and will control its position of disengaging (spatial control).Spatial control can realize in the holdup time of gastric by the prolongation system.Effectively local under one's belt as medicine, the advantage of gastrointestinal tract gaseous-waste holdup system is just more.At the medicine that upper gastro-intestinal tract absorbs, its absorbed situation can be because of the different differences to some extent of emptying and gastrointestinal peristalsis situation in inside of human body and the interpersonal stomach.The difference of this absorption aspect can solve with regulating the drug dose mode, allows contain the medicine that sub-fraction is promptly released in the medicament, and contains the medicine of most of slow release or controlled release.
Being used for one of the method for implementation space control is to come the formation system with containing with the compositions of the blended high expanded polymer of gas-forming agent, and its volume is increased, and is floated in the gastric juice, thereby increases the gastric retention of slow release or controlled release medicament releasing system.Density reduces in the system because the generation of gas and inducing action make, and the system that contains expanded polymer can float in the gastric juice immediately, and this be that the professional in present technique field is generally acknowledged.Expanding into bigger volume is a key factor of system's gastric retention.From stomach, discharge under the situation on the feed less than 5 to 7 millimeters solids more slow, but they still can from stomach, discharge because their volume is less than sphincter of pylorus.Lie on the back as patient, size also can be discharged from less than 5 to 7 millimeters the system of floating.The average diameter of pylorus is about the 13+7 millimeter when static, and the medicine type that has report to claim diameter dimension under the swelling state to be about the 12-18 millimeter can not pass through sphincter of pylorus usually.System also should be able to cause in gastric peristalsis under the state of stirring in that gastric juice is medium-term and long-term and keep such size.The complete system of size digests when the period of digestion begins and can not be discharged from before the travel motion complex wave arrives like this.Allow volume increase, and simultaneously can be floating, make that the gastric retention of system is prolonged.Below the look-ahead technique of developing according to prior art is described.
Authorize the Incorporated Foundation Microbial Chemistry Research the 4th, 101,650 (' 650) number U.S. Patent Publication a kind of prescription, this prescription in, contain sodium bicarbonate, the granule of lactose and polyvinylpyrrolidone is wrapped one deck hydroxypropyl emthylcellulose.And then wrap the suspended substance that one deck contains active component pepsin inhibitor and hydroxypropyl emthylcellulose in the above, form the floating microcapsule of diameter in 0.1 to 2 millimeter scope.The shortcoming of this system is that microcapsule is significantly smaller than required size in the long-time delay stomach dimensionally.
Authorize a kind of low cellulose hydrocarbyl ether, polyacrylic acid or its pharmaceutical acceptable salt, oral long lasting drug formulations of medicine and effective dose foaming agent of containing of the 4th, 777,033 (' 033) number U.S. Patent Publication of Supreme Being people company.But the major defect that the tablet made from said composition still has ' 650 look-ahead technique described is because the tablet of ' 033 system can not be kept perfectly in decomposition run.
Authorize outstanding person company the 4th, 844, No. 905 U.S. Patent Publication a kind of by pastille nuclear, the intermediate layer takes place in the gas of being made up of sodium carbonate and organic acid, and the granule of the skin formation of an expandable polymer film formation.Although its objective is and want to stay in the stomach that this granule still has the little shortcoming of volume.
Authorize Sai Liya new drug Industrial Co., Ltd No. 63014715 Japanese patent publication a kind of slow releasing composition, said composition contains (A) high viscosity water soluble (CO) polymers, preferably cellulose ether or polyvinyl alcohol, (B) insoluble crospolyvinylpyrrolidone, and (C) a kind of composition that can foam that contacts with gastric juice, preferably carbonate, particularly calcium carbonate or winnofil.It is promptly to release the medicine of form that this system does not still comprise a part, and another part is the medicine of controlled release forms, does not possess for two stages to disengage mode.Therefore, even when also not having medicine in the body at the beginning of taking medicine, system also can be to disengage medicine than promptly releasing the slow relatively speed of compositions.Another shortcoming is that high the expansion may meet the requirement of gastric retention with rapid expansible polymer, but we find several cellulose ethers to be arranged and do not meet this requirement.
Authorize the 5th of Beyer Co., Ltd, 651, No. 985 United States Patent (USP) has proposed a kind of medicinal activity compositions, comprise a kind of polyvinylpyrrolidone and the medicinal activity chemical compound of acid number in the molecular level homogeneous mixture of every gram solid polymer methacrylic acid polymer of potassium hydroxide between 100 to 1200 milligrams of being scattered in, gas generation additive also can be arranged.It is promptly to release the medicine of form that this system does not still comprise a part, and another part is the medicine of controlled release forms, does not possess for two stages to disengage mode.The expansion rate of this system is also slow, and consequently it can not reach required size in 15 to 30 minutes short time.In addition, make two kinds of polymer reach unanimity on the molecular level, required as freeze drying process, not only bother but also expensive.
The WO00/15198 Patent Cooperation Treaty international application of Lan Bakesai laboratory application relates to a kind of medical composition, comprises a kind of medicine, and a kind of gas produces compositions, a kind of extender, and a kind of thickening agent also can comprise a kind of gel formation polymer.Used gas producing agent is carbonate or bicarbonate.Extender splits agent for super, as crospolyvinylpyrrolidone, and crosslinked hydroxy methocel and dealing with alcohol Starch Sodium.Thickening agent is a kind of carbohydrate natural gum that can improve viscosity rapidly.This system does not comprise that still a part is promptly to release the medicine of form, and another part is the medicine of controlled release forms, does not possess for two stages to disengage mode.
The WO01/10419 Patent Cooperation Treaty international application of Lan Bakesai laboratory application relates to a kind of medical composition, comprise a kind of medicine, a kind of sugar, a kind of diluent and a kind of gas producing agent, the WO01/10405 Patent Cooperation Treaty international application that also is the application of Lan Bakesai laboratory relates to a kind of medical composition, comprises a kind of medicine, inert oil, a kind of sugar, a kind of diluent and a kind of gas producing agent.These systems still can not expand into the required size of delay in stomach, because they do not contain any expandable material.
The WO00/23045 Patent Cooperation Treaty international application of Sai Nuofei-Sheng Delabao application discloses and has a kind ofly comprised two or trilaminar medical composition, contains a kind of active medical components and changes its excipient that disengages and energy produces the system of carbon dioxide in the hydrophilic matrix of expanded polymer.In the example that provides, active component is in containing expanded polymer that layer as its excipient that disengages of change, and the second layer then contains expanded polymer and carbonate.Compositions is two-layer or trilaminar tablet.It is promptly to release the medicine of form that this system does not still comprise a part, and another part is the medicine of controlled release forms, does not possess for two stages to disengage mode.
The WO01/10417 Patent Cooperation Treaty international application of Jia Longni development company application discloses and proposes a kind of medical composition, comprise at least one contain active medical components and one or more excipient first mutually, and one be called as inactive second phase, comprises that at least a gas produces system and at least a hydrophilic polymer or porous mineral chemical compound; Wherein active at least 80% the active component that contains mutually.Use has limited less than 20% the rate of disengaging control excipient should obtain the formulation flexibility that the required rate of disengaging guarantees each situation of producing in batches of disengaging high level repeatability again.On the other hand,, make to be the high repeatability that use amount seldom also wants to guarantee the situation of disengaging, so excipient high level expansion rapidly itself because the selection that disengages rate control excipient is wanted scrupulous.System among the WO01/10417 adopts and nonactively realizes floatingly mutually, promptly reduces in the nonactive phase matrix by carbon dioxide is enclosed in that density realizes.
Goal of the invention
An object of the present invention is to provide a kind of gastric retention controlled drug delivery system, comprising:
A. a controlled release medicated core comprises a kind of medicine, a kind of high expanded polymer and a kind of gas producing agent, and described medicated core can expand and realize floating in its physical integrity of the medium-term and long-term maintenance of gastro-intestinal Fluid rapidly, and
B. rapid release coating compositions, comprise with medicated core in same medicine and the pharmaceutically acceptable excipient of medicine, wherein the coating compositions wraps up medicated core, makes this system can allow medicine disengage in two stages in gastro-intestinal Fluid.
Moreover a particular object of the present invention provides a kind of gastric retention controlled drug delivery system of baclofen.
Brief summary of the invention
The invention provides a kind of gastric retention controlled drug delivery system, comprising:
(a) a controlled release medicated core comprises a kind of medicine, and a kind of high expanded polymer and a kind of gas produce chemical compound, and described medicated core can expand and realize floating in its physical integrity of the medium-term and long-term maintenance of gastro-intestinal Fluid rapidly, and
(b) rapid release coating compositions, comprise with medicated core in same medicine and the pharmaceutically acceptable excipient of medicine, the coating compositions wraps up medicated core, makes this system can allow medicine disengage in two stages in gastro-intestinal Fluid.
The present invention also provides a kind of gastric retention controlled drug delivery system, and its controlled release medicated core can be expanded to about twice of original volume at least rapidly, and can be at medium-term and long-term its physical integrity that keeps of gastro-intestinal Fluid.
The present invention also provides a kind of gastric retention controlled drug delivery system that contains baclofen or its pharmaceutically acceptable salt.
Brief description of drawings
Fig. 1 represents to take the embodiment post plasma bulk concentration and the time relation situation of the gastric retention of the present invention control delivery system that contains 30 milligrams of baclofens.
Detailed description of the invention
The invention provides a kind of gastric retention controlled drug delivery system, comprising:
(a) a controlled release medicine core comprises a kind of medicine, a kind of high expanded polymer and a kind of γ-ray emission compound, and described medicine core can expand rapidly and realize floating in its physical integrity of the medium-term and long-term maintenance of gastro-intestinal Fluid, and
(h) quick-release coating composition, comprise with the medicine core in same medicine and the pharmaceutically acceptable excipient of medicine, the coating composition wraps up the medicine core, so that this system can allow medicine disengage in two stages in gastro-intestinal Fluid.
Gastric retention controlled drug delivery system of the present invention can be used to provide improved medicine and disengage. The medicine that can be used for gastric retention controlled drug delivery system of the present invention can be selected from following medicine, and namely hangover medicine is treated the dementia medicine, arcotic, acromegalia curative, anodyne, the treating asthma medicine, anticarcinogen, anticoagulant, antithrombotic, antiepileptic (anticonvulsants), medicine for treating diabetes, antiemetic, Antiglaucoma agent, antihistamine, anti-medicine, Parkinson's disease curative, the blood platelet curative of infecting, antirheumatic drug, anti-spasm and cholinergic drug, antitussive, carbonic anhydrase inhibitor, the cardiovascular treatment medicine, CHE (cholinesterase) inhibitor, nervous centralis disorder treatment medicine, central nervous excitation agent, contraceptive, the cystic fibrosis curative, dopamine receptor gaonist, endometritis curative, the erectile dysfunction curative, the infertility treatment medicine, gastrointestinal drug, immunomodulator, immunodepressant, strengthen the memory medicine, antimigraine preparation, loosening all muscles medicine, the nucleosides analogue compounds, the osteoporosis therapy medicine is intended the parasympathetic nerve curative, prostaglandin, spirit (psychotherapeutic) curative, calm, hypnosis and neuroleptic agent, treating skin disease medicine, steroids and hormone.
The example of acromegaly curative such as Octreotide (octreotide), dodecapeptide and pegvisomant (pegvisomant).
The example of hangover medicine such as clorazepate (chlorazepate), chloride (chlordiazepoxide) librium, stable, antialcoholic (disulfiram), quench pine (naltrexone) and its esters are taken in dimension Taining (hydroxyzine).
The example of arcotic such as adrenaline (adrenalinr), this cacaine of cloth (bupivacaine), chloroprocanine, desflurane (desflurane), Etidocaine, levobupivacaine, lidocaine, midazolam, Propofol, sieve croak cacaine and its esters.
The example of anodyne such as paracetamol, aspirin, bupivacaine; Buprenorphine, butorphanol (butorphanol), gram west inside competition (celecoxib); Chlophedianol, choline, clonidine; Codeine, difunisal (diflunisal), dichloro codeine; Dihydroergotamine, paramorphane, dionin; Etodolac complies with Qu Qingtan (eletriptan), Eptazocine (eptazocine); Ergotamine, fentanyl, fentoprofen; Hyaluronic acid; The hydrogenation codeinone, hydromorphone, Hai Lanjia (hylan); Ibuprofen (ibuprofen); Lindomethacin, ketorolac (ketorolac), Ketotifen (ketotifen); Levothyl; Levallorphan, feed on a hydroxyl first left side, lidocaine; Mefenamic acid; Meloxicam, meperidine, methadone; Morphine; Nabumetone, Numorphan Oral, nalorphine; Naloxone (naloxine); Take the pine (naltrexone) of quenching, naproxen, naratriptan (naratriptan); Nefazodone (nefazodone); Mormethadon, oxaprozine, hydroxyl dihydrocodeinone; Numorphan; Pentazocine, pethidine, Sauteralgyl; Pehnpyramid; Piritramid, piroxicam (piroxicam), the third oxygen sweet smell; Rofecoxib (refecoxib); Rizatriptan (rizatriptan), salsalaketoprofen, sulindac; Sumatriptan (sumatriptan); Tebaeon, the vertical fourth of pain, Tolmentin Sodium (tolmetin); C16H25NO2, zolmitriptan (zolmitriptan) and its esters.
The example of antiasthmatic such as Ablukast (ablukast), azelastine (azelastine), Bunaprolast (bunaprolast), Cinalukast (cinalukast), cromitrile (cromitrile), Cromoglycic acid, Enofelast (enofelast), two fourths are disliked amine, acid Ketotifen (ketotifen), levcromekalin, Lodoxamide, montelukast (montelukast), ontazolast (ontazolast), Oxarbazole, Oxatomide (oxatomide), piriprost potassium (piriprost potassium), Pirolate, pool is than a spy (pobilukast edamine), Quazolast (quazolast), Repirinast (repirinast), Ritolukast (ritolukast), Sulukast (sulukast), tetrazolastmeglumine, tiaramide (tiaramide), Tibenelast (tibenelast), Tomelukast (tomelukast), tranilast (tranilast), verofylline (verlukast), dichloro-dimethyl first butyl purinone, zarirlukast.
The example of cancer therapy drug such as adriamycin (adriamycin), Aldesleukin (aldesleukin), allopurinol, hemel, Amifostine (amifostine), arimidex (anastrozole), asparaginase, betamethasone, bexarotene, Bicalutamide (bicalutamide), bleomycin A5, busulfan, capecitabine (capecitabine), card handkerchief, Carmustine, Chlorambucil, cis-platinum, Cladribine (cladribine), conjugated estrogen, cortisone, endoxan, cytarabine, Dacarbazine, daunorubicin, D actinomycin D, denileukin, dexamethasone, discodermolide, taxotere (docetaxel), adriamycin, eloposidem, epirubicin, Epoetin (epoetin), Ai Pu Shillong (epothilones), estramustine, esterified estriol, ethinyl estradiol, Etoposide, Exemestane (exemestane), flavopirdol, Fluconazole (fluconazole), fludarabine (fludarabine), fluorine is urinated sweet pyridine, Flutamide, fluorine glycosides, gemcitabine (gemcitabine), WAY-CMA 676 (gemtuzumab), Goserelin (goserelin), hexamethylene diamine, hydrocortisone, hydroxycarbamide, idarubicin (idarubicin), ifosfamide, interferon, Irinotecan (irinotecan), lemiposide, Trastuzumab associating Letrozole (letrozole), L-tetramisole, a kind of gonadotropin releasing hormone analogues, levothyrocine, Luo Mosiding, mechlorethamine, melphalan, the mercaptopurine mechlorethamine, acetic acid megestrol acetate, methotrexate (MTX), methylprednisolone, Methyltestosterone, mithramycin, mitomycin, mitotane, mitoxantrone, Mitozolomide (mitozolomide), mutamycin, Nilutamide (nilutamide), taxol (paclitaxel), the handkerchief rice hydrochlorate (pamidronate) of seeing, Pegaspargase (pegaspargase), Pentostatin (pentostatin), plicamycin (plicamycin), porphines nurse (porfimer), deoxy-cortisol, procarbazine, Rituximab (rituximab), Sargramostim (sargramostim), Semustine, streptozotocin, TAM, temozolamide, the semi-synthetic derivative of podophyllotoxin, Testolactone, the mercapto guanine, phosphinothioylidynetrisaziridine, Tomudex (tomudex), TPT (topotecan), Toremifene (toremifene), trastumuzab, Vitamin-A Acid, CH3-CCNU, streptozotocin, valrubicin, verteprofin, vincaleukoblastinum, vincristine, eldisine, Vinorelbine and its esters.
The example of anticoagulant and thrombolytic medicine such as isocyanides acetone coumarin, reach heparin (dalteparin), heparin, booth is pricked heparin (tinzaparin), Enoxaparin (enoxaparin), danaparoid (danaparoid), abciximab (abciximab), Alprostadil, altiplase, anagralide, anistreplase (anistreplase), argatroban (argatroban), ataprost (ataprost), Beraprost (beraprost), camonagreel, cilostazol (cilostazol), clinprost (clinprost), clopidogrel (clopidogrel), cloricromen (cloricromen), dermatan, De Xilu pyridine (desirudin), domitroban (domitroban), drotaverine (drotaverine), epoprostenol (epoprostenol), dust is for crust peptide (eptifibatide), fradafiban (fradafiban), gabexate (gabexate), iloprost (iloprost), isbogrel (isbogrel), lamifiban (lamifiban), new plasminogen activator (lamoteplase), Lefradafiban (lefradafiban), lepirudin (lepirudin), levosimendan (levosimendan), lexipafant (lexipafant), melagatran (melagatran), nafagrel (nafagrel), nafamostsat, nizofenone (nizofenone), orbifiban, ozagrel (ozagrel), pamicogrel (pamicogrel), handkerchief heparin (parnaparin), quinobendan, reteplase (reteplase), sarpogralate, Satigrel (satigrel), silteplase (silteplase), simendan (simendan), platelet suppressant drug, vapiprost (vapiprost), tirofiban (tirofiban), xemilofiban (xemilofiban), Y20811 and its esters.
Anticonvulsant medicine such as carbadipimidine, clonazepam, stable, two valproic acids (divalproex), ethosuximide, ethotoin, felbamate (felbamate), fosphenytoin (fosphenytoin), gabapentin (gabapentin), lamotrigine (lamotrigine), levetiracetam (levetiracetam), lorazepam (lorazepam), mephenytoin (mephenytoin), enphenemal, metharbital, the first amber is pressed, oxcarbazepine (oxcarbazepine), phenobarbital, phenytoin,, primidone mysoline, tiagabine (tiagabine), topiramate (topiramate), valproic acid, vigabatrin (vigabatrin), zonisamide (zonisamide), and its esters.
The medicine such as the acarbose (acarbose) of treatment diabetes; acetohexamide; carbutamide (carbutamide), chlorpropamide (chlorpropamide), epalrestat (epalrestat); glibornuride (glibornuride); gliclazide (gliclazide), glimepiride (glimepiride), glipizide (glipizide); gliquidone (gliquidone); glisoxepid, glibenclamide (glyburide), glyhexamide (glyhexamide); metformin; miglitol (miglitol), Nateglinide (nateglinide), Orlistat (orlistat); Phenbutamide (phenbutamide); pioglitazone (pioglitazone), repaglinide (repaglinide), rosiglitazone (rosiglitazone); first sulphur nitrogen grass urea; tolbutamide (tolbutamide), tolcyclamide, tolrestat (tolrestat); troglitazone (troglitazone), voglibose (voglibose) and its esters.
The example of Bendectin such as alprazolam, benzchinamide, benzetropine, train his histamine, chlorpromazine, dexamethasone, diphenidol (difenidol), dimenhydrinate, diphenhydramine (diphenhydramine), dolasetron (dolasetron), the many ketone of dopan (domperidone), dronabinol (dronabinol), droperidol (droperidol), granisetron (granisetron), haloperidol, lorazepam (lorazepam), meclizine (meclizine), prednisolone, paspertin metoclopramide, ondansetron (ondansetron), perphenazine, prochlorperazine, phenergan, scopolamine, tributine, triethylperazine, triflupromazine (triflupromazine), trimethobenzamide (trimethobenzamide), tropisetron (tropisetron) and its esters.
The example of glaucoma treatment medicine such as alprenoxime, dapiprazole (dapiprazole), dipivefrine, latanoprost (latanoprost), naboctate (naboetate), pirnahine and its esters.
Antihistaminic example such as acrivastine (acrivastine), activastine, albuterol (albuterol), this fourth of nitrogen (azelastine), bitolterol (bitolterol), Alimemazine (alimemazine), amlexanox (amlexanox), this fourth of nitrogen (azelastine), benzydamine (benzydamine), brompheniramine (brompheniramine), cetirizine (cetirizine), the bent rice of chlorine, cimetidine (cimetidine), clemastine (clemastine), cycloheptazine, Cyproheptadine, diclofenac (diclofenac), diphenhydramine (diphenhydramine), dotarizine (dotarizine), ephedrine (ephedrine), epinastine (epinastine), epinephrine, ethylnorepinephrine, fenpoterol, fexofenadine (fexofenadine), flurbiprofen (flurbiprofen), hydroxyzine, ibuprofen, isoetharine, isoproterenol, ipratropium bromide (ipratropium bromide), Ketoralac ammonia (ketorolac), levocetirizine (levocetirizine), loratidine, mequitazine (mequitazine), orciprenaline (metaproterenol), phyenlephrinium, phenylpropanolamine (phenylpropanolamine), pirbuterol (pirbuterol), promethazine (promethazine), pseudoepedrine, pyrilamine, salmaterol (salmeterol), terbutaline (terbutaline), tranilast (tranilast), xanthine derivative, xylometazoline and its esters.
Anti-infective exemplary agents such as Abacavir (abacavir), albendazole, amantadine, amphotericin, amino hydroxyl butyl kanamycin, para-aminosalicylic acid, the hydroxyl benzylpcnicillin, ampicillin, amprenavir (amprenavir), atovaquin, azithromycin (azithromycin), aztreonam (aztreonam), Carbenicillin, cephalo chlorine, the cefadroxil card, cefadole, cefazolin sodium, cefdinir (cefdinir), cefepime (cefepime), cefixime (cefexime), cefoperazone (cefoperazone), cefotaxime, cefotitam, cefoperazone (cefoperazone), cefoxitin (cefoxitin), cefpodoxine, cefprozil (cefprozil), ceftazidime, ceftibuten (ceftibuten), ceftizoxime, ceftriaxone sodium, cefuroxime (cefuroxime), cefalexin, chloroquine, cidofovir (cidofovir), cilastatin (cilastatin), clindamycin, clarithromycin (clarithromycin), clavulinic acid, clindamycin (clindamycin), polymyxin E methanesulfonic acid (colistimethate), dalfopristine, dapsone, daunomycin, delavirdin, demeclocycline (demeclocycline), didanosine (didanosine), doxycycline, amycin, Stocrin (efavirenz), enoxacin (enoxacin), erythromycin (erythromycin), ethambutol, ethionamide, famsiflovir, fluconazole, flucytocin, foscarnet, fosfomycin, ganciclayir, Gatifloxacin (gatifloxacin), griseofulvin, hydroxychloroquine, imipenum (imipenem), indinavir (indinavir), interferon, iso-nicotinic acid tincture (isoniazide), itraconazole (itraconazole), ivermectil, ketoconazole (ketoconazole), lamivudine (lamivudine), levofloxacin (levofloxacin), linizolid, lomefloxacin (lomefloxacin), lovacarbef, mebendazole, mefloquine (mefloquine), meropenem (meropenem), methanamine, spirit is dripped in spirit, minocycline, moxefloxacin, naldixicacid, viracept see nelfinaivr (nelfinavir), neomycin, nevirapine (nevirapine), nitorfurantoin, norfloxacin (norfloxacin), ofloxacin (ofloxacin), Oseltamivir (oseltamivir), oxytetracycline, palivizumab (palivizumab), penicillin, pefloxacin (perfloxacin), piperacillin (piperacillin), praziquantel (praziquantel), the arsenic carboxamide dihydrochloride, pyrimethamine, quinidine, quinupristine, retonavir, virazole, rifabutine, rifampicin, rimantadine (rimantadine), saquinavir (saquinavir), Sparfloxacin (sparfloxacin), stavudine (stavudine), streptomycin, sulfamethoxazole (sulfamethoxazole), teramycin, Terbinafine (terbinafine), tetracycline, card XiLin (ticarcillin), Apl-Luster, tobramycin, trimethoprim, trimetraxate, triacetyloleandomycin (troleandomycin), trovafloxacin (trovafloxacin), cut down Xi Luowei (valacyclovir), vancomycin, zalcitabine (zalcitabine), Zha Namiwei (zanamivir), zidovudine (zidovudine) and its esters.
Treat parkinsonian exemplary agents such as amantadine, adrogolide, altinicline, benzetropine, biperiden (biperiden), Ba Lafenxin (brasofensine), bromocriptine, budipine (budipine), cabergoline (cabergoline), CHF-1301, dihydrexidine, peace tolcapone (entacapone), quick releasing type levodopa (etilevodopa), idazoxan (idazoxan), iometopane, lazabemide (lazabemide), melevodopa, carbidopa/levodopa (carbidopa/levodopa), mofegiline (mofegiline), moxiraprine (moxiraprine), pergolide (pergolide), pramipexole (pramipexole), quinelorane (quinelorane), rasagiline (rasagiline), ropinirole (ropinirole), seligiline, talipexole (talipexole), tolcapone (tolcapone), trihexyphenidyl and its esters.
The example of antirheumatic such as azathipriine, betamethasone, gram inside competition west (celecoxib), ciclosporin (cyclosporin), diclofenac (diclofenac), hydroxychloroquine, indometacin, the sharp former times monoclonal antibody (infliximab) of English, mercaptobutanedioic acid, prednisolone, naproxen, penicillamine, piroxicam (piroxicam), prednisolone, sulfasalazine (sulfasalazine) and its esters.
Hematoblastic medicine example such as abciximab (abciximab), anagrelide (anagrelide), aspirin, cilostazol (cilostazol), clopidogrel (clopidogrel), dipyridamole (dipyridamole), prostacyclin, dust is for crust peptide (eptifibatide), platelet suppressant drug, tinofiban and its esters.
Control spasm and anticholinergic exemplary agents such as aspirin, atropine, dichloramine sodium phenylacetate, hyoscyamine, mesoprostol, methocarbamol, phenobarbital, scopolamine and its esters.
The example of antitussive such as acetaminophen, acrivastine (acrivastin), albuterol (albuterol), benzonatate, beractant, brompheniramine (brompheniramine), caffeine, calfactant, pentoxyverine (carbetapentane), the bent rice of chlorine, codeine, colfuscerin, dextromethorpham, dornase alpha, doxylamine, epinephrine, fexofenadine (fexofenadine), guaphenesin, ipratropium bromide (ipratropium), Levalbuterol (levalbuterol), orciprenaline (metaproterenol), montelukast (montelukast), pentoxyphyline, phyenlephrinium, phenylpropanolamine HC1 (phenylpropanolamine), pirbuterol (pirbuterol), pool draws smooth (poractant) alpha, pseudoephedrine (pseudoephedrine), pyrilamine, albuterol (salbuterol), salmaterol (salmeterol), terbutaline (terbutaline), theophylline, zafirlukast (zafirlukast), zileuton (zileuton) and its esters.
The example of carbonic anhydrase inhibitors such as acetazolamide, daranide (dichlorphenamide), dorzolamide (dorzolamide), U.S. house imidazoles, sezolamide (sezolamide) and its esters.
Cardiovascular diseases's medicine example such as abciximab (abciximab), acebutolol, Ah Ti general (activase), adenosine, epinephrine, amidarone, amiloride, amlodipine (amlodipine), amylnitrate, atenolol, atorvastatin (atorvastatin), benzepril, bepiridil, betaxalol, bisoprolol (bisoprolol), Candesartan (candesartan), captopril (captopril), cartenolol, carvedilol (carvedilol), cerivastatin (cerivastatin), chlortalidone, chlorthiazole, clofibrate (clofibrate), clonidine, colestipol (colestipol), colosevelam, digoxinm, diltiazem (diltiazem), norpace (disopyramide), dobutamine, dofetilide (dofet ilide), doxazosin (doxazosin), enalapril (enalapril), epoprostenol (epoprostenol), Eprosartan (eprosartan), esmolol (esmolol), etacrynic acid (ethacrynate), erithritol (erythrityl), felodipine (felodipine), fenoidapam, good fortune good fortune Puli (fosinopril), flecainide (flecainide), flurosemide, fluvastatin (fluvastatin), gemfibrozil (gemfibrozil), hydrochlorothiazide, naclex, ibutilide (ibutilide), indopamide (indapamide), isosorbide, Irb (irbesartan), labetalol (labetolol), lacidipine (lacidipine), lisinopril (lisinopril), Losartan (losartan), lovastatin (lovastatin), mecamylamine, metaprolol, metarminol, metazolone, methylchlothaizide, methyldopa, metyrosine, mexiletine (mexiletine), midrodine, milrinonr, moexipril (moexipril), nadolol (nadolol), Ni Yasi, nicardipine (nicardipine), nicorandil (nicorandil), nifidepine, nimodipine (nimodipine), nisoldipine (nisoldipine), nitroglycerine, phenoxybenzamine (phenoxybenzamine), increase diindyl Puli (perindopril), many thiazines, general Liprevil (pravastatin), prazosin (prazosin), procainamide (procainamide), Propafenone (propafenone), propranolol, clonidine (quanfacine), quinapril (quinapril), quinidine, ranipril, reteplase (reteplase), simvastatin (simvastatin), first sulphur are felt at ease fixed (sotalol), spironolactone, streptokinase (streptokinase), telmisartan (telmisartan), terazosin (terazosin), timolol (timolol), tocainamide, torasemide (torsemide), trandolapril (trandolapril), this pteridine of ammonia, trapidil (trapidil), valsartan (valsarian) and its esters.
The example of cholinesterase inhibitor such as donepezil (donepezil), edrophone chloride, neostigmine, this bright (pyridostigmine) of bromination pyrrole, tartaric acid Rivastigmine (rivastigmine), tacrine (tacrine) and its esters.
The example of central nervous excitation agent such as caffeine, doxapram (doxapram), dexoamphetamine, donepezil (donepezil), edorphonium, methamphetamine, methylphenidate, modafinil (modafinil), neostigmine, azoxodone, this butylamine, pyridostigmine, tartaric acid Rivastigmine (rivastigmine), tacrin and its esters.
The example of contraceptive such as desogestral, ethinyl estradiol, ethynodiol, left-handed norethindrone (levonorgestrel), medroxyprogesterone, norquen mestranol, Norgestimate (norgestimate), norethindrone, methylnorethindron and its esters.
The example of cystic fibrosis medicine such as dornase alpha, pancreatic lipase (pancrelipase), Top's imidazoles and its esters.
The example of dopamine receptor gaonist such as amantadine, cabergoline (cabergoline), fenoldopam (fenoldopam), pergolide (pergolide), pramipezal, ropinirole (ropinirole) and its esters.
Endometriotic medicine example such as danazol, goserelin (goserelin), leuprorelin (leuprolide), nafarelin (nafarelin), norethindrone (norethindrone) and its esters.
The exemplary agents such as the Alprostadil (alprostadil) of treatment erection problem, sldenafil (sildenafil), Yohimbine and its esters.
Treat sterile exemplary agents such as citrorelix, but Luo Mifen (clomiphen), follitropin, ganirelix (ganirelix), promoting sexual gland hormone, menotropin, progesterone, Urofollitropin (urofollitropin) and its esters.
The example of gastrointestinal drug such as alosetron (alosetron), nigalax (bisacodyl), basic bismuth salicylate, gram west inside competition (celecoxib), difoxin, dipheoxylate, many storehouses ester (docusate), famotidine (famotidine), glycopyrrolate, the sharp former times monoclonal antibody (infliximab) of English, lansoprazole (lansoprazole), chlorobenzene croak amide, paspertin metoclopramide (metaclopramide), the Buddhist nun pricks for you (nizatidine), omeprazole (omeprazole), Pantoprazole (pantoprazole), rabeprazole (rabeprazole), ranitidine, Simethicone (simethicone), sucralfate, and its esters.
The example of immunomodulator and immunosuppressant such as azathioprine (azathioprin), ceftizoxine, ciclosporin (cyclosporin), Zenapax (daclizumab), glatiramer, immunoglobulin, interferon, leflunomide (leflunomide), levamisole (levamisol), Mycophenolic Acid (mycophenolate), mausomanab, phthalidomide, ribavirin (rfbavirine), sirolimus (sirolimus) and its esters.
The example of dementia medicine such as CP 118954, donepezil (donepezil), galantamine hydrobromide, Metrifonate (metrifonate), revastigmine, tacrine (tacrine), TAK-147 and its esters.
The exemplary agents such as the acetaminophen of treatment migraine, dihyroergotamine, two valproic acids (divalproex), Ergotamine, propranolol, risatriptan, sumatriptan (sumitriptan), trimetrexate (trimetrexate) and its esters.
The example of medicine of flaccid muscles such as fluorinated diene third Tuo Fulin (alcuronium-chloride), azapropazon, atracurium (atracurium), baclofen, carisoprodol, quinine derivative, chloromezanon, chlorophenesincarbamate, chlorozoxazon, cyclobenzaprine (cyclobenzaprine), dantrolen, decamethoniumbromide, dimethyltubocurariniumchloride, spread storehouse ammonium (doxacurium), fenyramidol (fenyramidol), gallamintriethiodide more, guaiphensine, hexafluoreniumbromide, hexacarbacho-linbromide, memantin, mephenesin (mephenesin), miltown, metamisol, metaxalon, methocarbamol (methocarbamol), mivacurium (mivacurium), orphenadrin, Pavulon, phenazon, phenprobamate (phenprobamate), pipecuronium bromide (pipecuronium), Raplon (rapacuronium), Rocuronium Bromide (rocuronium), succinylcholine, Choline Chloride Succinate (suxamethoniumchloride), tetrazepam (tetrazepam), tizanidine (tizanidinc), Lv Huaguanjiandujian, tybamate (tybamate), vecuronium bromide (vecuronium) and its esters.
In the preferred embodiment of gastric retention controlled drug delivery system, of flaccid muscles medicinal be baclofen or its pharmaceutically acceptable salt.Before the present invention, do not know, disclose or proposed the baclofen gastric retention controlled drug delivery system.
The consumption of baclofen in system can be from 15 milligrams to 80 milligrams.In gastric retention controlled drug delivery system of the present invention, the consumption of baclofen is 30 milligrams.The design of system is to allow the baclofen major part of 30 milligrams of dosage in medicated core, and controlled disengaging allows the sub-fraction medicine promptly release in coating.Like this, delivery system of the present invention has just had disengaging of two stages of baclofen.
The example of nucleoside homologue such as Abacavir (abaeavir), acyclovir (acyelovir), didanosine (didanosine), gameiclovir, gemcitabine (gemcitabine), lamivudine (lamivudine), ribavirin, stavudine (stavudine), zalcitabine (zalcitabine) and its esters.
Treat osteoporotic exemplary agents such as alendronate (alendronate), calcitonin, estradiol, OES piperazine (estropipate), medroxyprogesterone, norethindrone, norgestimate (norgestimate), Pamidronic Acid salt (pamidronate), raloxifene (raloxifen), risdronate, Zoledronate salt (zoledronate) and its esters.
The example of parasympathomimetic agent such as urecholine, biperidine, edrophone chloride, glycopyrolate, hyoscyamine, pilocarpine, tacrine (tacrine), Yohimbine and its esters.
The example of medicine for prostate disease such as Alprostadil, prostacyclin, misoprostol (misoprostol) and its esters.
The example of psychotherapy's medicine such as acephenazine acetophenazine, alentemol (alentemol), alpertine (alpertine), alprazolam (alprazolam), amitriptyline, apriprazole, azaperone (azaperone), batelapine (batelapine), befipiride, benperidol (benperidol), benzindopyrine (benzindopyrine), bimithil, biriperone (biriperone), brofoxine; Bromperidol (bromperidol); Bromperidol (bromperidol), amfebutamone (bupropion), buspirone (buspirone), butaclamol (butaclamol), butyrylperazine, butyrylperazine, the card fen is which piperazine, carvotroline (carvotroline), Cericlnmine (eericlamine), chlorazepine, chlordiazepoxide, chlorpromazine, chlorprothixene (chlorprethixene), cinperene (cinperene), cintramide (cintriamide), citalopram (citalopram), clomacrane, clonazepam, clopenthixol (clopenthixol), clopimozide, clopipazan (clopipazan), cloroperone, clotiapine, clothixamide, clozapine, ciclofenazine, dapiprazole (dapiprazole), dapoxetine (dapoxetine), desipramine (dcsipramine), two valproic acids (divalproex), dipyridamole (dipyridamole), doxepin, droperidol (droperidol), Luo Xiting (duloxetinc), eltoprazine (eltoprazine), eptipirone, etazolate (etazolate), fenimide (fenimide), flibanserin, flucindole, flumezapine (flumezapine), fluoxetine, fluphenazine, fluspiperone, fluspirilene, flutroline (flutroline), fluvoxamine (fluvoxamine), gepirone (gepirone), gevotroline (gevotroline), halopemide (halopemide), haloperidol, hydroxyzine, hydroxynortriptyline, iloperidone (iloperidone), imidoline (imidoline), lamotrigine (lamotrigine), loxapine (loxapine), enperone, Mazapertine (mazapertine), enphenemal (mephobarbital), miltown, mesoridazine, mesoridazine, midalcipran (milnacipran), mirtazapine (mirtazepine), metiapine, milenperone (milenperone), benzene piperazine second is drawn, morpholine draws ketone, nafadotride, Naranol, nefazodone (nefazodone), neflumozide (neflumozide), ocaperidone (ocaperidone), odapipam, olanzapine (olanzapine), oxethiazine, oxiperomide (oxiperomide), pagoclone (pagoclone), paliperidone, paroxitene, the benzene R-33204., pentiapine (pentiapine), perphenazine, phenelzine, pimozide, pinoxepin (pinoxepin), pipamperone (pipamperone), piperacetazine (piperacetazine), pipotiazine (pipotiazine), piquindone (piquindone), pirlindole (pirlindole), pivagabine (pivagabine), pramipexole (pramipexole), prochlorperazine, prochlorperazine, promazine, Quetiapine (quetiapine), reboxetine (reboxetine), remoxipride (remoxipride), remoxipride (remoxipride), risperidone (risperidone), rimcazole (rimcazole), robolzotan, selegiline (selegiline), clofluperol (seperidol), Sertraline (sertraline), Sertindole (sertindole); Seteptiline, setoperone (setoperone), spiperone (spiperone), sunipitron, tepirindole (tepirindole), thioridazine, thiothixene, tiapride (tiapride), tioperidone, tiospirone (tiospirone), topiramate (topiramate), tranylcypromine, trifluoperazine, trifluperidol (trifluperidol), triflupromazine (triflupromazine), triflupromazine (triflupromazine), trimeprimine (trimipramine), venlafaxine (venlafaxine), Ziprasidone (ziprasidone) and its esters.
Calm, hypnosis, the example of neuroleptic agent such as bromazepam (bromazepam), buspirone (buspirone), clazolam (clazolam), clobazam (clobazam), chlorazepate (chlorazepate), stable, demoxepam (demoxepam), dexmedetomitine, diphenyhydramine, doxylamine, enciprazine (enciprazine), estrazolam, hydroxyzine, ketazolam (ketazolam), lorazatone, lorazepam (lorazepam), loxapine (loxapine), dechlorination is stable, pethidine, mcthobarbital, midazolam (midazolam), nabilone (nabilone), nisobamate (nisobamate), oxazepan pentobarbital, phenergan, propofol (propofol), triazolam (triazolam), Zaleplon (zaleplon), azoles pyrrole dawn (zolpidem) and its esters.
Treat dermopathic exemplary agents such as acitretin (acitretin), alclometasone (alclometasone), allitretinoin, betamethasone (betamethasone), caiciprotrine, chlohexidine, clobetasol (clobetasol), clocortolone, clotriamozole, collagenase, ring born of the same parents enzyme element, desonide, difluorosonc, doxepin (doxepine), eflornithine (eflornithine), Finasteride (finasteride), fluocinolone acetonide (fluocinolone), flurandrenolide, fluticasone (fluticasone), halogen is his rope (halobetasol) doubly, hydrochloroquine, hydroquinone, hydroxyzine, ketoconazole, mafenide, Malathion, menobenzone, neostigmine, nystatin, podophyllin element (podofilox), polyvidone (povidone), tazorotene, Vitamin-A Acid, and its esters.
The example of steroid and hormone such as alclometasone (alclometasone), betamethasone (betamethasone), calcitonin, citrorelix, clobetasol (clobetasol), clocortolone, cortisone, danazol, Desmopressin, desonide, desogestrel (desogestrel), desoximetasone (desoximetasone), dexamethasone, Diflorasone, estradiol, estrogen, estrone sulfuric ester piperazine (estropipate), ethynlestradiol, fluocinolone acetonide (fluocinolone), flurandrenolide, fluticasone (fluticasone), glucagon, promoting sexual gland hormone, goserelin (goserelin), halogen is pine (halobetasol) doubly, hydrocortisone, a kind of gonadotropin releasing hormone analogues, left-handed norethindrone (levonorgestrel), levothyroxine sodium, medroxyprogesterone, menotrophin (menotropins), prednisolone, Methyl testosterone, momestasone furoate (mometasone), naferelin, norditropin, norethindrone, methylnorethindron, octreolide, oxandrolone (oxandrolone), adroyd, polytropin, prednicarbate (prednicarbate), prednisolone, progesterone, Sermorelin (sermorelin), growth hormone (somatropin), stanozolol (stanozolol), testosterone, Urofollitropin (urofollitropin) and its esters.
According to the present invention, medicated core obtains high level expansion in the short time.Obtaining high level expansion can be by adopting high the expansion, rapid expansible polymer, or by avoiding the high pressure compressed expanded polymer, or employing itself is compressed to low-density high expanded polymer.When compressed medicated core density was low, medicated core just had enough intensity, if wrap one deck coating by compression, it also can be delivered to second compressor station that wraps from its compressed first compressor station with machinery; If also will be by spraying row coating again, it also can stand the stirring in the coating machine.
The example of the available high expanded polymer of the present invention comprises:
The cellulose ether of energy high level expansion, as hydroxyl C1-4 alkyl C1-4 alkyl cellulose, carboxycellulose, hydroxyl C1-4 alkyl cellulose is preferably hydroxyethyl-cellulose, hydroxypropyl cellulose, hydroxypropyl emthylcellulose is best with the high viscosity hydroxyethyl-cellulose.
Plant, animal, mineral or rubber polymer are as the agar that (i) obtains from sea-plant, alginate, chondrus ocellatus Holmes, furcellaran glue, the (ii) guar gum that obtains from the ground plant, arabic gum, tragacanth, POLY-karaya, Hibisci Mutabilis angle glue, (iii) microorganism polysaccharide is as glucosan Collettii Column glue, Fructus rhamni (Rhamnus davurica Pall.) glue, xanthan gum, and (iv) synthetic or semi-synthetic glue, as propylene glycol alginate, hydroxypropyl guar gum, super polymer such as crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, the carboxymethyl starch of splitting, modified starch, as sodium starch glycol, methacrylate potassium-divinylbenzene copolymer, polyvinyl alcohol, polysaccharide, cross-linked polysaccharides, starch derivatives, microcrystalline Cellulose, and cellulose derivative, α-, β-, γ-cyclodextrin, and dextrin derivative; Acrylate copolymer is as the cross linked polymer of commodity card by name ripples (Carbopol);
Vinylpyrrolidone polymer is as crospolyvinylpyrrolidone or crospovidone; The copolymer of vinylpyrrolidone and ethyl acetate; Or its mixture.
In a preferred embodiment, high expanded polymer is the super mixture that splits polymer and one or more adhesive, and adhesive is from hydrophilic polymer, selects in the preferably high expanded polymer.In a preferred embodiment, used hydrophilic polymer is that a kind of its aqueous solution viscosity scope is about the full-bodied cellulose derivative of 500 milli handkerchiefs to about 120000 milli handkerchiefs.In one embodiment of the invention, used the preferred expanded polymer of mixture of Sodium Carboxymethyl Starch and high viscosity hydroxylated cellulose.In another embodiment of the present invention, used the preferred expanded polymer of mixture of Sodium Carboxymethyl Starch and high viscosity hydroxyethyl-cellulose and hydroxypropyl emthylcellulose.
Sodium Carboxymethyl Starch is the sodium salt of the carboxylic methyl ether of starch, and molecular weight is 500,000 to 1,000,000 dalton, and commodity are by name With
Figure G02812857519940610D000192
Sodium Carboxymethyl Starch is fissioned when meeting water rapidly, sharply expands rapidly immediately.Using Sodium Carboxymethyl Starch is that its effectiveness can be because of there not being hydrophilic excipient as the super advantage of splitting agent, as the existence of lubricant and the influence of influenced or the pressure that increased.It can be expanded to 300 times of its volume in water.In the present invention, Sodium Carboxymethyl Starch is used as the preferred super agent of splitting, its consumption be medicated core weight about 5% to about 50%, be preferably medicated core weight about 10% to about 40%, be more preferably about 15% to about 30% of medicated core weight.
Hydroxyethyl-cellulose is a kind of non-ionic water-soluble polymer, is poly-(ethoxy) ether of the metathetical cellulose of a kind of part, and its viscosity and displacement degree have various specification.Commodity have the Sai Luosaisi (Cellosize from Amerchol Corp.) of A Meikaer company and that Te Luosuoer of A Kualong company ( From Aqualon).In the present invention, using its aqueous solution viscosity is preferable for 2% weight/volume hydroxyethyl cellulose aqueous solution of the extremely about 30000 milli handkerchiefs of about 9000 milli handkerchiefs as hydrophilic polymer.Its consumption be medicated core weight about 5% to about 50%, serve as better with about 10% to about 40% of medicated core weight, serve as better with about 15% to about 30% of medicated core weight.
Hydroxypropyl emthylcellulose (HPMC) is partial oxygen-methyl and oxygen-(2-hydroxypropyl) cellulose, and its viscosity has various specification.The molecular weight of HPMC is 10,000 to 1,500,000 dalton.Its commodity are for originally being plug (Benecel MHPC), Mei Suosai (Methocel) and U.S. Toro department (Metolose).In one embodiment of the invention, used the HPMC of K4M level to make expanded polymer, its consumption be medicated core weight about 5% to about 25%, be preferable with about 10% to about 15% of medicated core weight.
In a preferred embodiment, with the mixture of high viscosity hydroxyethyl-cellulose and Sodium Carboxymethyl Starch make high expanded polymer, its weight ratio scope preferably is a hydroxyethyl-cellulose: Sodium Carboxymethyl Starch is between 1: 9 to 9: 1, be more preferably its ratio between 3: 7 to 7: 3, also will be good be that its ratio is between 4: 6 to 6: 4.The medicated core that forms with this mixture can expand and realize floating rapidly, keeps its physical integrity simultaneously for a long time.
The gas-forming agent that gastric retention controlled drug delivery system of the present invention is used can be the single component that can produce gas when contact gastric juice, also can be used in combination.The available gas generation of the present invention composition comprises carbonate such as calcium carbonate, heavy carbonate such as sodium bicarbonate or potassium, and sulphite such as sodium sulfite, sodium bisulfite, or sodium metabisulfite or the like.These salt can use separately, also can combine with acid source to do the gas generation.Acid source can be an edible organic acid, edible organic acid salt or its mixture.Available organic acid example comprises citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, maleic acid, ascorbic acid, glutamic acid or its esters and mixture.The consumption of gas-forming agent be medicated core weight about 1% to about 50%, be preferably about 1% to about 15% of medicated core weight.Is preferable with sodium bicarbonate as gas-forming agent.
High expanded polymer can also comprise a kind of excipient that can increase the delivery system expansion rate again.This excipient can be that infiltrative water soluble compound is arranged, or a kind of suction agent, and as microcrystalline Cellulose, it can promote water to flow into system.Suitable water soluble compound comprises penetration material, be penetrating agent or penetration material (osmogents), comprise that all are in pharmacopeia, as American Pharmacopeia, and show at Lei Mingdun (Remington) that said pharmaceutically acceptable and pharmacology goes up inert water soluble compound in " medical science with put into practice ".Pharmaceutically acceptable water-soluble inorganic salt or organic acid, or highly-water-soluble nonionic organic compound, for example carbohydrate such as sucrose or aminoacid are all fine.The example that can produce chemosmotic penetrating agent comprises inorganic salt, as magnesium chloride or magnesium sulfate, and lithium chloride, sodium or potassium, lithium hydrogen phosphate, sodium or potassium, lithium dihydrogen phosphate, sodium or potassium, acylate is as sodium acetate or potassium, Magnesium succinate, sodium benzoate, sodium citrate or sodium ascorbate; Carbohydrate such as mannitol, Sorbitol, Radix Acaciae senegalis, ribose, xylose, glucose, fructose, mannose, galactose, sucrose, maltose, lactose, melitriose; Water-soluble amino acid such as carbohydrate gum, leucine, alanine or methionine, carbamide or the like, with and composition thereof.In a preferred embodiment, the medicated core of gastric retention controlled drug delivery system comprises that one or more can improve the penetrating agent of system's expansion rate.The consumption of penetrating agent is preferable with about 0.5% to about 50% of medicated core weight, more preferably about 2% of medicated core weight to about 40%.
Gastric retention controlled drug delivery system of the present invention can also comprise various pharmaceutically acceptable excipient, disintegrant for example, and as starch, cellulose derivative, resin, cross linked polymer or the like; Binding agent, as starch, gel, sucrose, cellulose derivative, polyvinylpyrrolidone or the like; Lubricant, as Talcum, magnesium stearate, dioxide/silica gel, Polyethylene Glycol, cellulose derivative or the like; With and composition thereof.
In a preferred embodiment, use hydroxypropyl emthylcellulose (HPMC) as binding agent.The most handy HPMC K4M makes binding agent, and consumption is preferable with about 0.2% to about 5% of medicated core weight, with medicated core weight about 0.2% to about 2% for better.
The example of the available lubricant of the present invention such as Talcum, magnesium stearate, calcium stearate, aluminium stearate, stearic acid, hydrogenation vegetable oil, dioxide/silica gel, Polyethylene Glycol, cellulose derivative is as carboxyethyl cellulose and alkali salt or its mixture.In a preferred embodiment, used lubricant is the mixture of silicic acid microcrystalline Cellulose Talcum and polyvinyl alcohol.The silicic acid microcrystalline Cellulose is the potentiation close physical mixture of a kind of microcrystalline Cellulose and dioxide/silica gel, and particle size is 20 to 200 microns, generally includes the dioxide/silica gel of 2% weight.Commodity are called Bo Lasuofu
Figure G02812857519940610D000211
SMCC), compare with microcrystalline Cellulose, it is better that it compresses performance.Used Polyethylene Glycol (PEG) is PEG 8000.The consumption that is used as the mixture of lubricant is preferable with about 0.5% to about 40% of medicated core weight, is preferable with about 5% to about 30% of medicated core weight, is the best with about 10% to about 25% of medicated core weight.
The medicated core of gastric retention controlled drug delivery system by comprise with medicated core in same medicine of medicine and the coating compositions of promptly releasing formed of pharmaceutically acceptable excipient wrap up.In a preferred embodiment of the invention, this coating compositions comprises baclofen and pharmaceutically acceptable excipient, as film forming agent, and plasticizer or the like.Film forming agent is selected from the one group of material that comprises cellulose ether and ester, as methylcellulose, and ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl emthylcellulose (HPMC); Acrylate copolymer, as methacrylate, methacrylate copolymer or the like, with and composition thereof.In a preferred embodiment, hydroxypropyl emthylcellulose is used as film forming agent, and its consumption is good with about 0.5% to about 5% of medicated core weight, with medicated core weight about 1% to about 3% for better.Promptly release compositions and can also comprise one or more plasticizers of from following one group of material, selecting: glycerol, propylene glycol, polyethylene glycol; the acetyl group mono glycerinate, citrate is as triethyl citrate; phthalic acid ester is as phthalic acid ester diethyl phthalic acid ester.In a preferred embodiment, propylene glycol is used as plasticizer.In addition, the commerce that also happy Kanggong department of section (Colorcon) can be gone out handkerchief difficult to understand by name get profit II ( II) hydroxypropyl emthylcellulose lining solution comes the applying controlled medicated core of releasing with medicament mixed.
The manufacturing of lining tablet can divide two steps.In first manufacturing step, at first compressor station medicated core compositions is injected mould, compress, pour out with the low pressure punch press.Second step is to use traditional method, as spraying or the extrusion coating that is covered.In the spraying seal coat, to expose its surface, will comprise that simultaneously medicine and the polymeric coating composition of lining apply up by allowing medicated core in suitable coating container, roll or being allowed to condition to flow in the mobile units.Medicine can be contained in the compositions that comprises lining group polymer by liquid media, perhaps can adopt the form integrator of powder layer.The compression lining is included in second compressor station coating composition is injected the Lower Half that mould prepares to do tablet, medicated core is transported to second compressor station from first compressor station, and be placed on the central authorities of the coating composition that injects mould, the coating composition of the first half is injected mould, compress the formation tablet with the low pressure punch press at compression stage, will compress good tablet in the stage of pouring out and from mould, pour out.
Gastric retention controlled drug delivery system of the present invention can expand rapidly, keeps its physical integrity simultaneously for a long time in gastric juice.Be retained in by the gas that gas-forming agent is produced and make density reduce in the system, system just floatability in gastric juice.Expansion can take place rapidly with the reservation of gas, so system can be in 15 minutes, to float in 10 minutes in the solution that contains 0.1 equivalent concentration hydrochloric acid to good.
Following Example is used for describing, and does not limit scope of invention.
Example 1
According to the form below 1 is made gastric retention controlled drug delivery system.
Table 1
Figure G02812857519940610D000221
The method for making of the medicated core of gastric retention controlled drug delivery system is with baclofen, lactose, hydroxyethyl-cellulose, sodium starch glycollate, sodium bicarbonate and a part of HPMC K4M sieve with No. 40 sieves of ASTM (American Society for Testing and Materials), each composition mixing is obtained mixture dry powder, and the aqueous solution of using HPMC K4M is with the powder mixture pelletize.The granule that obtains is sieved and drying with suitable sieve.Dried granules Prosolv SMCC 90, Talcum, PEG 8000 is lubricated with the mixture of HPMC K4M, is pressed into medicated core.With the aqueous solution lining medicated core that contains baclofen and OpadryII, make gastric retention controlled drug delivery system of the present invention then.
With American Pharmacopeia II type (slurry formula) dissolution equipment, the rotating speed in that per minute 50 changes carries out solubility test to the tablet that makes like this under 37 ℃ the temperature.Used dissolving medium are 1000 milliliter of 0.1 equivalent concentration hydrochloric acid.The tablet that makes is floating when having spent about 10 minutes.The result of solubility test is as shown in table 2 below.
Table 2
Time The percentage ratio that disengages at 0.1N HCl Chinese medicine
0? 0?
1? 39?
2? 44?
4? 53?
6? 60?
8? 66?
12? 77?
Example 2
According to the form below 3 is made gastric retention controlled drug delivery system.
Table 3
The method for making of the medicated core of gastric retention controlled drug delivery system is with baclofen, mannitol, hydroxyethyl-cellulose, sodium starch glycollate, sodium bicarbonate sieves with No. 40 sieves of ASTM (American Society for Testing and Materials), each composition mixing is obtained mixture dry powder, and the aqueous solution of using HPMC K4M is with the powder mixture pelletize.The granule that obtains is sieved and drying with suitable sieve.Dried granules is lubricated with Prosolv SMCC 90, the mixture of Talcum and PEG 8000, is pressed into medicated core.Then with containing baclofen, HPMC E5, Talcum, the water-alcohol solution lining medicated core of the mixture of propylene glycol makes gastric retention controlled drug delivery system of the present invention.
With American Pharmacopeia II type (slurry formula) dissolution equipment, the rotating speed in that per minute 50 changes carries out solubility test to the tablet that makes like this under 37 ℃ the temperature.Used dissolving medium are 1000 milliliter of 0.1 equivalent sodium chloride (0.1N HCl).The tablet that makes has been crossed about 6 minutes floating.The result of solubility test is as shown in table 4 below.
Table 4
Time The percentage ratio that disengages at 0.1N HCl Chinese medicine
0? 0?
1? 55?
2? 63?
4? 75?
6? 83?
8? 91?
12? 99?
Example 3
According to the form below 5 is made gastric retention controlled drug delivery system.
Table 5
Composition Amount (milligram/sheet)
Baclofen 30.0?
Hydroxyethyl-cellulose (Natrosol 250H) 197.5?
Sodium starch glycollate 217.5?
Microcrystalline Cellulose (Avicel PH 101) 435.0?
Sodium bicarbonate 10.0?
Polyvinylpyrrolidone (PVP K-30) 22.0?
Talcum 9.0?
Magnesium stearate 9.0?
With a part of baclofen, hydroxyethyl-cellulose, a part of sodium starch glycollate, a part of microcrystalline Cellulose mixes with a part of polyvinylpyrrolidone, and is lubricated with Talcum and magnesium stearate with the isopropyl alcohol pelletize, makes the medicated core granule.With remaining baclofen, microcrystalline Cellulose, polyvinylpyrrolidone mixes with sodium starch glycollate, mixes with water, forms grain coating, and compacted layer of this medicated core granule and use compress this coating are used for medicated core.The gastric retention controlled drug delivery system of the lining tablet form that makes like this can be in the short time high level expansion, enough processing intensity is arranged, in water liquid, can be kept perfectly, and can provide two stage medicines to disengage.
Example 4
The baclofen of taking after the gastric retention controlled drug delivery system (example 2) that contains 30 milligrams of baclofens is carried out pharmacokinetic study.This has also been carried out multi-agent and single agent, open label at random, compares and two-way exchange research.
The pharmacokinetics assessment is what to carry out according to the baclofen plasma density that records in the blood sample.Blood sample be before taking medicine with take behind the trial drug-0.25,0.5,1,1.5,2,2.5,3,4,6,8,12,12.5,13,13.5, obtained in 14,15,16,20 and 24 hours.
12 healthy male volunteers have participated in research, and the somebody of institute has finished research.Subjects is taken medicine and is not taken food last night, higher fatty acid breakfast of feed before taking medicine.Took medicine preceding 2 hours, and take medicine and forbade drinking water in back 2 hours, but other times can at will be drunk.Take medicine back 4 hours with 8 hours and after this appropriate time pay standard meal.The food and drink of two periods is identical.
Subjects after fasting, was taken the gastric retention control medicine that single agent contains baclofen (30 milligrams) with 240ml water under the room temperature and is disengaged tablet in 5 days.
The blood sample of different time points collection is carried out the plasma density of baclofen and measure, obtain 12 volunteers' meansigma methods.Data see the following form 6.Plasma density and time relation are seen accompanying drawing 1.
Table 6
Time (hour) Baclofen gastric retention control medicine disengages the average plasma density (nanograms/milliliter) of tablet (30 milligrams)
0? 0?
0.25? 0.97?
0.5? 12.95?
1.0? 81.57?
1.5? 117.42?
2.0? 141.46?
2.5? 154.1?
3.0? 157.67?
4.0? 172.88?
6.0? 155.77?
8.0? 119.55?
12.0? 67.38?
12.5? 65.28?
13.0? 60.20?
13.5? 57.01?
14.0? 52.26?
15.0? 48.18?
16.0? 40.07?
20.0? 28.03?
24.0? 18.87?
Gastric retention controlled drug delivery system is fit to day clothes once.

Claims (19)

1. gastric retention controlled drug delivery system, its feature comprises:
(a) a controlled release medicated core comprises a kind of medicine, a kind of expanded polymer and a kind of gas producing agent, and wherein said expanded polymer is selected from:
The expansible cellulose ether of energy is characterized in that the expansible cellulose ether of described energy is selected from hydroxyl C1-4 alkyl C1-4 alkyl cellulose, carboxycellulose, and hydroxyl C1-4 alkyl cellulose,
Plant, animal, mineral or rubber polymer
The super polymer that splits describedly superly splits polymer and is selected from crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch, carboxymethyl starch sodium, methacrylate potassium-divinylbenzene copolymer, polyvinyl alcohol, polysaccharide, cross-linked polysaccharides, starch derivatives, sodium starch glycollate; Microcrystalline Cellulose, and cellulose derivative, α-, β-, γ-cyclodextrin, and dextrin derivative;
Acrylate copolymer; With
Vinylpyrrolidone polymer
And
(b) rapid release coating compositions, comprise with medicated core in same medicine and the pharmaceutically acceptable excipient of medicine,
Wherein the coating compositions wraps up medicated core, the selection of wherein said expanded polymer and gas producing agent and consumption make works as American Pharmacopeia II type (slurry formula) dissolution equipment with described system, in 1000 milliliters of 0.1N HCl under the rotating speed that per minute 50 changes, floating 15 minutes of described system or still less when carrying out solubility test under 37 ℃ the temperature
And wherein this system can allow medicine disengage in two stages in gastro-intestinal Fluid.
2. gastric retention controlled drug delivery system according to claim 1, wherein said glue is selected from the agar that (i) obtains from sea-plant, alginate, chondrus ocellatus Holmes, furcellaran glue, the (ii) guar gum that obtains from the ground plant, arabic gum, tragacanth, POLY-karaya, Hibisci Mutabilis angle glue, (iii) microorganism polysaccharide, described microorganism polysaccharide comprises glucosan ， Collettii Column glue, Fructus rhamni (Rhamnus davurica Pall.) glue, xanthan gum, and (iv) synthetic or semi-synthetic glue, comprise propylene glycol alginate, the hydroxypropyl guar gum.
3. gastric retention controlled drug delivery system according to claim 1 is characterized in that described acrylate copolymer is the cross linked polymer of commodity card by name ripple.
4. gastric retention controlled drug delivery system according to claim 1 is characterized in that described vinylpyrrolidone polymer is selected from crospolyvinylpyrrolidone, the copolymer of vinylpyrrolidone and ethyl acetate, or its mixture.
5. gastric retention controlled drug delivery system according to claim 1, it is characterized in that described expanded polymer is (a) super agent polymer and (b) mixture of hydrophilic polymer of splitting, wherein said super to split the agent polymer be from crospolyvinylpyrrolidone, selects in one group of material of cross-linking sodium carboxymethyl cellulose and sodium starch glycollate formation.
6. gastric retention controlled drug delivery system according to claim 5 is characterized in that described sodium starch glycollate consumption is 10% to 40% of a medicated core weight.
7. gastric retention controlled drug delivery system according to claim 5 is characterized in that described super to split agent be sodium starch glycollate, and sodium starch glycollate is 4: 6 to 6: 4 with the ratio of hydroxyethyl-cellulose.
8. gastric retention controlled drug delivery system according to claim 1 is characterized in that used hydrophilic polymer is that its aqueous solution viscosity is the high viscosity cellulose derivative of 500 milli handkerchief to 120000 milli handkerchiefs in 2% weight/volume aqueous solution.
9. gastric retention controlled drug delivery system according to claim 8 is characterized in that described high viscosity cellulose derivative is the hydroxyethyl-cellulose of 9000 milli handkerchief to 30000 milli handkerchiefs for its aqueous solution viscosity in 2% weight/volume aqueous solution.
10. gastric retention controlled drug delivery system according to claim 9 is characterized in that the hydroxyethyl-cellulose consumption is 15% to 30% of a medicated core weight.
11. gastric retention controlled drug delivery system according to claim 1 is characterized in that described gas-forming agent is from carbonate, heavy carbonate, sulfate with and composition thereof select in one group of material constituting.
12. gastric retention controlled drug delivery system according to claim 1, it is characterized in that gas-forming agent also comprises from the organic acid citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, maleic acid, ascorbic acid, the acid source of selecting in one group of material that glutamic acid or its esters and mixture constitute.
13. gastric retention controlled drug delivery system according to claim 1 is characterized in that used gas-forming agent is a sodium bicarbonate.
14. gastric retention controlled drug delivery system according to claim 13, the consumption that it is characterized in that sodium bicarbonate are 1% to 15% of medicated core weight.
15. gastric retention controlled drug delivery system according to claim 1 is characterized in that described controlled release medicated core also comprises penetrating agent.
16. gastric retention controlled drug delivery system according to claim 15, the consumption that it is characterized in that described penetrating agent are 2% to 40% of medicated core weight.
17. gastric retention controlled drug delivery system according to claim 1 is characterized in that described medicine is a baclofen.
18. gastric retention controlled drug delivery system according to claim 5 is characterized in that describedly super split the agent polymer and being selected from: crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch, carboxymethyl starch sodium, methacrylate potassium-divinylbenzene copolymer, polyvinyl alcohol, polysaccharide, cross-linked polysaccharides, starch derivatives, microcrystalline Cellulose, and cellulose derivative, α-, β-, γ-cyclodextrin, and dextrin derivative.
19. the purposes of baclofen in the preparation gastric retention controlled drug delivery system, described system comprises that baclofen or its pharmaceutically acceptable salt are used for taking medicine once a day of people, and the back of taking medicine was at 3-8 hour peak plasma bulk concentration and at least 24 hours the baclofen plasma density of maintenance for baclofen; Wherein said gastric retention controlled drug delivery system comprises:
(a) a controlled release medicated core comprises a part of baclofen, a kind of expanded polymer and a kind of gas producing agent, and wherein said expanded polymer is selected from:
The expansible cellulose ether of energy is characterized in that the expansible cellulose ether of described energy is selected from hydroxyl C1-4 alkyl C1-4 alkyl cellulose, carboxycellulose, and hydroxyl C1-4 alkyl cellulose,
Plant, animal, mineral or rubber polymer
The super polymer that splits describedly superly splits polymer and is selected from crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch, carboxymethyl starch sodium, methacrylate potassium-divinylbenzene copolymer, polyvinyl alcohol, polysaccharide, cross-linked polysaccharides, starch derivatives, sodium starch glycollate; Microcrystalline Cellulose, and cellulose derivative, α-, β-, γ-cyclodextrin, and dextrin derivative;
Acrylate copolymer; With
Vinylpyrrolidone polymer
And
(b) promptly release compositions for one, comprise a part of baclofen and pharmaceutically acceptable excipient,
The selection of wherein said expanded polymer and gas producing agent and consumption make works as American Pharmacopeia II type (slurry formula) dissolution equipment with described system, in 1000 milliliters of 0.1N HCl under the rotating speed that per minute 50 changes, floating 15 minutes of described system or still less when carrying out solubility test under 37 ℃ the temperature
And wherein this system can allow medicine disengage in two stages in gastro-intestinal Fluid.
CN028128575A 2001-07-04 2002-07-04 Gastric retention controlled drug delivery system Expired - Lifetime CN1520286B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN612/MUM/2001 2001-07-04
IN612MU2001 2001-07-04
PCT/IN2002/000144 WO2003011255A1 (en) 2001-07-04 2002-07-04 Gastric retention controlled drug delivery system

Publications (2)

Publication Number Publication Date
CN1520286A CN1520286A (en) 2004-08-11
CN1520286B true CN1520286B (en) 2010-12-01

Family

ID=32051199

Family Applications (1)

Application Number Title Priority Date Filing Date
CN028128575A Expired - Lifetime CN1520286B (en) 2001-07-04 2002-07-04 Gastric retention controlled drug delivery system

Country Status (17)

Country Link
US (2) US7776345B2 (en)
EP (2) EP2238975B1 (en)
JP (2) JP4994570B2 (en)
KR (1) KR20040018394A (en)
CN (1) CN1520286B (en)
AT (1) ATE477795T1 (en)
AU (1) AU2002355686B2 (en)
BR (1) BR0211317A (en)
CA (1) CA2452738C (en)
DE (1) DE60237372D1 (en)
ES (1) ES2398348T3 (en)
HU (1) HUP0500795A3 (en)
MX (1) MXPA03012041A (en)
PL (1) PL370793A1 (en)
RU (1) RU2325152C2 (en)
WO (1) WO2003011255A1 (en)
ZA (1) ZA200400799B (en)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
ES2296956T5 (en) * 2001-06-11 2011-07-12 Xenoport, Inc. GABA ANALOGUE PROPHARMACS, COMPOSITIONS AND THEIR USES.
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
PL370793A1 (en) * 2001-07-04 2005-05-30 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
CZ20041175A3 (en) * 2002-06-04 2005-04-13 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system and process for preparing thereof
US8679533B2 (en) 2002-07-25 2014-03-25 Pharmacia Corporation Pramipexole once-daily dosage form
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
KR101140559B1 (en) 2003-08-20 2012-07-05 제노포트 인코포레이티드 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
CN1929823A (en) * 2003-12-12 2007-03-14 宾韦斯特医药公司 Sustained release torsemide dosage forms
WO2005060942A1 (en) * 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Extended release pharmaceutical composition of metformin
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
UA88477C2 (en) 2004-08-13 2009-10-26 Бёрингер Ингельхайм Интернациональ Гмбх Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
FR2874325B1 (en) * 2004-08-19 2006-10-20 Sanofi Synthelabo PHARMACEUTICAL COMPOSITION IN THE FORM OF A GASTRIC RESISTANCE COMPRESSOR CONTAINING ALFUZOSIN
DE102004042139B4 (en) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Peroral dosage forms to achieve a retarding effect after drug intake with a meal
WO2006044202A2 (en) * 2004-10-19 2006-04-27 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
WO2006050471A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006050472A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
CA2584338C (en) 2004-11-04 2013-08-06 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
WO2006084164A2 (en) 2005-02-01 2006-08-10 Emisphere Technologies, Inc. Gastric retention and controlled release delivery system
EP1690540A1 (en) * 2005-02-15 2006-08-16 Neuro3D Composition comprising ocaperidone
US8431156B2 (en) * 2005-02-22 2013-04-30 Sun Pharma Advanced Research Company Ltd. Pharmaceutical composition
MX2007010233A (en) 2005-02-23 2007-11-07 Teva Pharma Rasagiline formulations of improved content uniformity.
ATE396710T1 (en) * 2005-07-19 2008-06-15 Ethypharm Sa GASTRORETENTIVE COMPOSITIONS AND METHOD FOR PRODUCING
EP1957052A2 (en) * 2005-10-25 2008-08-20 Pharmascience Inc. A gastric retention drug delivery system
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
AU2007201808B8 (en) * 2006-04-26 2013-09-05 Sun Pharmaceutical Advanced Research Company Ltd A method for alleviating signs and symptoms of spasticity
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
SG10201503411QA (en) 2006-08-03 2015-06-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
CL2007002214A1 (en) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP
US20100016310A1 (en) * 2006-08-17 2010-01-21 Boehringer Ingelheim International Gmbh Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors
WO2008033572A1 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
KR102044064B1 (en) * 2006-09-26 2019-11-12 노파르티스 아게 Pharmaceutical compositions comprising an s1p modulator
US8795721B2 (en) 2006-12-18 2014-08-05 Eatlittle Inc. Device for delivery of a substance
CA2673665C (en) * 2006-12-22 2017-03-21 Ironwood Pharmaceuticals, Inc. Method and compositions for treating esophageal disorders
KR20080076382A (en) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 Controlled-release preparation containing cilostazol and process for the preparation thereof
CN101011393B (en) * 2007-02-16 2010-10-06 广州柏赛罗药业有限公司 Irbesartan gastric retention sustained-release pharmaceutical composition
DE102007026037A1 (en) 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentive system with alginate body
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) * 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
HUP0700469A2 (en) * 2007-07-09 2009-04-28 Richter Gedeon Nyrt Floating pharmaceutical composition of sustained release containing metronidazol
EP2192892A2 (en) * 2007-07-27 2010-06-09 Depomed, Inc. Pulsatile gastric retentive dosage forms
EP2175840A2 (en) * 2007-08-14 2010-04-21 Dr. Reddy's Laboratories, Ltd. Pharmaceutical compositions comprising ropinirole
WO2009069089A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Levetiracetam controlled release composition
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
WO2009097156A1 (en) * 2008-02-01 2009-08-06 Barr Laboratories, Inc. Pharmaceutical capsules comprising extended release dipyridamole pellets
US9457048B2 (en) 2008-02-05 2016-10-04 Wellosophy Corporation Absorbent ingestible agents and associated methods of manufacture and use
EP3115043B1 (en) 2008-04-18 2020-11-25 Intec Pharma Ltd. Carbidopa/levodopa gastroretentive drug delivery
ZA200903858B (en) * 2008-06-19 2013-10-30 Univ Of Witwatesrand Johannesburg Pharmaceutical dosage form
WO2009158625A2 (en) * 2008-06-26 2009-12-30 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders
CN102036654B (en) * 2008-07-24 2014-05-14 湖南洞庭药业股份有限公司 Stabilized atypical antipsychotic formulation
EP2326310B1 (en) * 2008-08-15 2019-05-15 Assertio Therapeutics, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
CA2745741A1 (en) 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
CA3014688A1 (en) 2008-12-19 2010-07-15 Supernus Pharmaceuticals, Inc. Use of molindone for the treatment of aggression, irritability, or impulsivity
AU2010207740B2 (en) * 2009-01-26 2016-06-16 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
US20100297195A1 (en) * 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Controlled release lamotrigine formulations
JP5614557B2 (en) * 2009-05-27 2014-10-29 ダサン メディケム カンパニー リミテッド Multi-layer tablet with foam layer
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US20110104273A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of phenylephrine
EP3517103A1 (en) * 2010-02-03 2019-07-31 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof
WO2011101866A2 (en) * 2010-02-17 2011-08-25 Sun Pharma Advanced Research Company Ltd., A method of treating a disease condition susceptible to baclofen therapy
WO2011123497A1 (en) 2010-03-31 2011-10-06 Supernus Pharmaceuticals Inc. Stabilized formulations of cns compounds
KR101270751B1 (en) * 2010-05-06 2013-06-07 (주)비씨월드제약 Composition for the gastric retention and controlled release of therapeutic agents
WO2011151708A1 (en) 2010-06-01 2011-12-08 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
RU2013135224A (en) * 2011-01-20 2015-03-10 Бионевиа Фармасьютикалс Инк. COMPOSITIONS WITH MODIFIED RELEASE OF EPALRESTAT OR ITS DERIVATIVES AND METHODS FOR USING THEM
AT511671A1 (en) * 2011-07-13 2013-01-15 Bischof Georg Dr COMPOSITION FOR GENERATING TEMPORARY OCCLUSION OF THE IMMUNE OF AN IMAGE AGENT
KR101438546B1 (en) * 2011-08-26 2014-09-17 근화제약주식회사 Controlled-release formulations comprising pregabalin
RU2489147C2 (en) * 2011-08-31 2013-08-10 Людмила Петровна Лазурина Local pharmaceutical antibacterial composition of active biometallic complexes
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN102440976A (en) * 2011-12-21 2012-05-09 南京海陵中药制药工艺技术研究有限公司 Epalrestat slow-release tablet and preparation method thereof
NZ700474A (en) 2012-04-18 2016-10-28 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
US9918937B2 (en) * 2013-01-30 2018-03-20 Daewoong Co., Ltd. Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract
US10166207B2 (en) 2013-06-05 2019-01-01 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
FR3014692B1 (en) * 2013-12-18 2016-01-29 Ethypharm Sa ORAL PHARMACEUTICAL COMPOSITIONS WITH GASTRIC RETENTION.
WO2016001843A1 (en) * 2014-06-30 2016-01-07 Sun Pharmaceutical Industries Limited Extended-release gastroretentive tablets of voglibose
WO2016132233A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release oral dosage form of gaba receptor agonist with enhanced pharmacokinetics
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
RU2649834C1 (en) * 2016-07-06 2018-04-04 Фармалидер С.А. Pharmaceutical composition of sildenafil citrate in form of suspension for oral administration
AU2017297718B2 (en) 2016-07-11 2023-06-08 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
FR3054218B1 (en) * 2016-07-22 2020-03-06 Universite De Rouen PROCESS FOR SPLITTING BACLOFENE SALTS
CN109922801B (en) 2016-09-09 2023-07-18 库蒂斯制药公司 Suspension and diluent of metronidazole and baclofen
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
EP3345591A1 (en) * 2017-01-06 2018-07-11 Oystershell NV Oral dosage form for enhanced solubilization of a poorly soluble active agent and method of preparation
WO2018127594A1 (en) * 2017-01-06 2018-07-12 Oystershell Nv Oral dosage form for enhanced solubilization of a poorly soluble active agent and method of preparation
JP6823539B2 (en) * 2017-05-26 2021-02-03 株式会社ファンケル Gastric retention tablets
US10987311B2 (en) * 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
DK3648747T3 (en) 2017-06-16 2022-11-28 Amneal Complex Products Res Llc Gastroretentive dosage forms for sustained release of drugs
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
WO2019051387A1 (en) * 2017-09-08 2019-03-14 Mingbao Zhang Methods of using dipivefrin
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
CN113476421B (en) * 2017-12-29 2023-04-07 江苏恒瑞医药股份有限公司 Controlled release composition of febuxostat and preparation method thereof
EP3824881B1 (en) * 2018-06-18 2022-02-16 Amneal Complex Products Research LLC Extended release compositions comprising pyridostigmine
BR112020026266A2 (en) * 2018-06-19 2021-03-30 National University Of Singapore 5-HYDROXYTHRIPTOPHAN (5-HTP) FORMULATIONS FOR BETTER AVAILABILITY FOR VARIOUS INDICATIONS
EP3628004B1 (en) 2018-06-27 2021-09-22 Amneal Complex Products Research LLC Self-regulating osmotic gastroretentive drug delivery systems
JP7044649B2 (en) 2018-06-28 2022-03-30 株式会社ファンケル Intragastric floating tablets
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
CA3139217A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
RU2751163C9 (en) * 2020-04-06 2021-10-20 Общество С Ограниченной Ответственностью "Ниармедик Плюс" Macozinone-based pharmaceutical composition for treatment of tuberculosis including multi- and extensively drug-resistant forms thereof
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
CA3238888A1 (en) * 2021-11-25 2023-06-01 Dennie Van Den Heuvel Gastro-retentive oral dosage unit containing a local anaesthetic
CN114796142A (en) * 2022-04-08 2022-07-29 黄山学院 Naproxen gastric floating tablet and preparation method thereof
CN115444831B (en) * 2022-10-25 2023-08-22 南京康川济医药科技有限公司 Epalrestat gastric floating tablet and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038650A1 (en) * 1998-12-23 2000-07-06 Alza Corporation Gastric retention dosage form having multiple layers
EP1095650A1 (en) * 1999-10-29 2001-05-02 Universiteit Leiden Double phase time-controlled release system

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4101650A (en) 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
SE8404467D0 (en) * 1984-09-06 1984-09-06 Ferrosan Ab CONTROLLED-RELEASE MEDICAL PREPARATIONS
DE3681348D1 (en) * 1985-06-11 1991-10-17 Teijin Ltd ORAL DRUG PREPARATION WITH RETARDIVE EFFECT.
JPS62195323A (en) 1986-02-24 1987-08-28 Eisai Co Ltd Gastric resident particle
US4772473A (en) * 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
JPH0798742B2 (en) 1986-07-03 1995-10-25 ゼリア新薬工業株式会社 Sustained release pharmaceutical composition
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US4892739A (en) * 1988-04-25 1990-01-09 Ciba-Geigy Corporation Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
PH26730A (en) * 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
DE4406424A1 (en) 1994-02-28 1995-08-31 Bayer Ag Expandable dosage forms
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
WO1997020551A1 (en) * 1995-12-05 1997-06-12 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
US6271278B1 (en) * 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
CA2290624C (en) * 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
IN186245B (en) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
BR9908911A (en) * 1998-03-19 2001-10-02 Bristol Myers Squibb Co Biphasic system and distribution process by controlled release of high solubility pharmaceutical substances
CZ2001901A3 (en) 1998-09-14 2001-08-15 Ranbaxy Laboratories Limited Pharmaceutical composition representing system of controlled delivery of a medicament for oral administration, providing time and local control
FR2784583B1 (en) 1998-10-16 2002-01-25 Synthelabo PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE
CA2354472C (en) * 1998-12-17 2009-02-24 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
WO2001008670A2 (en) 1999-07-29 2001-02-08 Interneuron Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
AU5060499A (en) 1999-08-04 2001-03-05 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
FR2797185B1 (en) 1999-08-06 2001-10-26 Galenix Dev FLOATING PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE AND A NON-ACTIVE PHASE
PL370793A1 (en) * 2001-07-04 2005-05-30 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
KR101140559B1 (en) * 2003-08-20 2012-07-05 제노포트 인코포레이티드 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
AU2007201808B8 (en) * 2006-04-26 2013-09-05 Sun Pharmaceutical Advanced Research Company Ltd A method for alleviating signs and symptoms of spasticity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038650A1 (en) * 1998-12-23 2000-07-06 Alza Corporation Gastric retention dosage form having multiple layers
EP1095650A1 (en) * 1999-10-29 2001-05-02 Universiteit Leiden Double phase time-controlled release system

Also Published As

Publication number Publication date
US7776345B2 (en) 2010-08-17
RU2003138075A (en) 2005-06-10
JP2004538301A (en) 2004-12-24
US20100305208A1 (en) 2010-12-02
CA2452738A1 (en) 2003-02-13
EP1411901B1 (en) 2010-08-18
US20040180088A1 (en) 2004-09-16
EP2238975A1 (en) 2010-10-13
EP1411901A1 (en) 2004-04-28
BR0211317A (en) 2004-12-14
US8012496B2 (en) 2011-09-06
CA2452738C (en) 2011-06-14
WO2003011255A1 (en) 2003-02-13
ZA200400799B (en) 2005-07-27
PL370793A1 (en) 2005-05-30
MXPA03012041A (en) 2004-03-26
AU2002355686B2 (en) 2007-11-29
JP2010090161A (en) 2010-04-22
KR20040018394A (en) 2004-03-03
CN1520286A (en) 2004-08-11
HUP0500795A3 (en) 2008-04-28
JP4994570B2 (en) 2012-08-08
EP2238975B1 (en) 2012-12-05
HUP0500795A2 (en) 2007-02-28
DE60237372D1 (en) 2010-09-30
RU2325152C2 (en) 2008-05-27
ES2398348T3 (en) 2013-03-15
ATE477795T1 (en) 2010-09-15

Similar Documents

Publication Publication Date Title
CN1520286B (en) Gastric retention controlled drug delivery system
AU2002355686A1 (en) Gastric retention controlled drug delivery system
US20060210633A1 (en) Programmed drug delivery system
EP1931320B1 (en) Microparticles with modified release of at least one active principle and oral dosage form comprising the same
Prinderre et al. Advances in gastro retentive drug-delivery systems
US20160338966A1 (en) Multimicroparticulate pharmaceutical forms foe oral administration
US20110268666A1 (en) Novel gastroretentive delivery system
WO2008140460A1 (en) Solid form
US20080286343A1 (en) Solid form
CN101422442A (en) Levetiracetam osmotic pump controlled release tablet and preparation method thereof
Hooda Gastroretentive drug delivery systems: A review of formulation approaches
Rashmitha et al. An update on floating drug delivery system: a review
Chen et al. Evaluation of water uptake and mechanical properties of blended polymer films for preparing gas‐generated multiple‐unit floating drug delivery systems
Thorat et al. BILAYER TABLET IS A NEW APPROACH
Lodhi et al. FLOATING MICROSPHERES A NOVEL APPROACH IN FLOATING DRUG DELIVERY SYSTEM A REVIEW
Gaikwad et al. GASTRORETENTIVE DRUG DELIVERY SYSTEMS: AN INNOVATIVE APPROACH TO ENHANCE ORAL DRUG BIOAVAILABILITY
Kumar et al. A REVIEW ON FLOATING TABLET
Ch et al. FORMULATION AND IN-VITRO EVALUATION OF FLOATING MATRIX TABLETS OF CIPROFLOXACIN HCL
Katiyar A Review Report on Important Approches of Floating Drug Delivery System
Kashyap et al. A BUOYANT APPROACH FOR RETENTIVE DRUG DELIVERY: FLOATING MICROSPHERES
Choudhary et al. International Journal of Modern Pharmaceutical Research
Sethy et al. FLOATING MATRIX TABLETS–A COMPLETE STUDY
Karuna et al. PHARMACEUTICAL SCIENCES

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SUN PHARMACEUTICAL ADVANCED RE

Free format text: FORMER OWNER: SUN PHARMA INC. LTD.

Effective date: 20120822

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20120822

Address after: India Maharashtra Mumbai Andrea -400093 (East) Mahathir Carrick Voss ROMAR Industrial Park 17/B Hal

Patentee after: SUN PHARMA ADVANCED RESEARCH CO.,LTD.

Address before: India Mumbai 400059 (East) Ande Ande black in black - Kulalu acme square

Patentee before: SUN PHARMACEUTICAL INDUSTRIES LTD.

CX01 Expiry of patent term

Granted publication date: 20101201

CX01 Expiry of patent term